Cerebral Infarction Treatment Global Market Report 2025

The cerebral infarction treatment market size has grown strongly in recent years. It will grow from $11.05 billion in 2024 to $11.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to higher healthcare expenditure, an increase in hospital admissions, a rise in minimally invasive stroke procedures, growing demand for mechanical thrombectomy devices, and an expansion in clinical trials.

The cerebral infarction treatment market size is expected to see strong growth in the next few years. It will grow to $15.54 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth in the forecast period can be attributed to the expanding geriatric population, a rising prevalence of stroke, an increase in cerebrovascular and cardiovascular diseases, and a growing incidence of cerebral infarction. Key trends expected during this period include the integration of telemedicine, the use of wearable health monitoring devices, advancements in neuroimaging techniques, the adoption of robotic-assisted surgery, nanotechnology-based drug delivery systems, and the development of virtual rehabilitation platforms.

The rising prevalence of stroke is anticipated to drive the growth of the cerebral infarction treatment market in the coming years. A stroke occurs when blood flow to the brain is disrupted or blocked, leading to a deficiency of oxygen and nutrients in brain tissue. This increase in stroke cases is largely attributed to the growing incidence of hypertension, which damages blood vessels and contributes to stroke risk. Cerebral infarction treatments play a crucial role in stroke care by restoring cerebral blood flow, minimizing long-term damage and disability. These treatments enhance patient outcomes through timely medical intervention, resulting in more effective and manageable recovery. For example, in September 2024, the Stroke Foundation, an Australia-based not-for-profit organization, reported that Australia experienced 45,785 stroke cases in 2023, with projections indicating a significant increase to 72,000 cases by 2050. Thus, the growing prevalence of stroke is a key factor fueling the expansion of the cerebral infarction treatment market.

Leading companies in the cerebral infarction treatment market are prioritizing the development of advanced technologies, such as dual aspiration technology, to reduce treatment time for patients with acute ischemic stroke. Dual aspiration technology involves the simultaneous use of two catheters to improve the efficiency of clot removal during stroke interventions. For example, in May 2025, Imperative Care, a U.S.-based medical technology company, introduced Zoom DuoPort, a cutting-edge stroke treatment device. This system supports dual aspiration by allowing two catheters to function concurrently with a single vacuum source. It enhances physician control, offers real-time procedural feedback, and increases the effectiveness of mechanical thrombectomy in treating acute ischemic stroke.

In March 2025, Medtronic plc, an Ireland-based medical device company, formed a partnership with Methinks AI to incorporate AI-powered stroke detection software into its neurovascular care solutions. The collaboration is intended to improve early stroke diagnosis, optimize triage processes, and enhance treatment outcomes, particularly in underserved areas. Methinks AI, a digital health company based in Spain, specializes in developing artificial intelligence solutions for the diagnosis and management of stroke.

Major players in the cerebral infarction treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, Medtronic plc, Amgen Inc., Siemens Healthineers, Becton, Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Penumbra Inc., Terumo Corporation, phenox GmbH, Boehringer Ingelheim International GmbH, Imperative Care Inc., Acandis GmbH & Co. KG, Reflow Medical Inc., Lumosa Therapeutics Inc., Insera Therapeutics Inc., Q’Apel Medical Inc.

North America was the largest region in the cerebral infarction treatment market in 2024. The regions covered in cerebral infarction treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cerebral infarction treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cerebral infarction treatment involves medical interventions designed to restore blood flow to the brain and limit the damage caused by a stroke resulting from blocked blood vessels (ischemic stroke). The primary goal of this treatment is to prevent additional brain injury, reduce neurological impairments, and enhance patient recovery.

The core types of treatment for cerebral infarction include medications, surgical procedures, and rehabilitation therapies. Medications used in this context aim to dissolve blood clots, regulate blood pressure, and prevent future strokes. Diagnostic methods employed in treatment consist of computed tomography (CT) scans, magnetic resonance imaging (MRI), angiography, and Doppler ultrasound. The treatment is applied to conditions such as ischemic stroke, transient ischemic attack, large artery stroke, and small vessel stroke, with end-users including hospitals, dedicated stroke centers, ambulatory surgical centers, and home care services.

The cerebral infarction treatment market research report is one of a series of new reports that provides cerebral infarction treatment market statistics, including cerebral infarction treatment industry global market size, regional shares, competitors with a cerebral infarction treatment market share, detailed cerebral infarction treatment market segments, market trends and opportunities, and any further data you may need to thrive in the cerebral infarction treatment industry. This cerebral infarction treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cerebral infarction treatment market consists of revenues earned by entities by providing services such as thrombolytic therapy administration, surgical interventions, rehabilitation programs, diagnostic imaging, and post-treatment patient care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The cerebral infarction treatment market also includes sales of anticoagulants, antiplatelet agents, thrombolytics, neuroprotective drugs, as well as medical devices such as stents, catheters, and diagnostic imaging equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.